A. Yang

发表

Changes in DNA methylation patterns in subjects exposed to low-dose benzene.

L. Hou, A. Baccarelli, V. Bollati, 2007, Cancer research.

A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements.

J. Issa, A. Yang, M. Estécio, 2004, Nucleic acids research.

DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia.

J. Issa, Lanlan Shen, A. Rashid, 2006, Cancer research.

Epigenetic profiling of somatic tissues from human autopsy specimens identifies tissue- and individual-specific DNA methylation patterns.

Kimberly D Siegmund, Peter W Laird, Hyang-Min Byun, 2009, Human molecular genetics.

Examination of IGF2 and H19 loss of imprinting in bladder cancer.

H. Byun, A. Yang, G. Liang, 2007, Cancer research.

Distinct pattern of p53 mutations in bladder cancer: relationship to tobacco usage.

A. Yang, P. Nichols, G. Hermann, 1993, Cancer research.

Development of romiplostim: a novel engineered peptibody.

A. Yang, 2015, Seminars in hematology.

Incorporation of Zebularine from its 2′-Deoxyribonucleoside Triphosphate Derivative and Activity as a Template-Coding Nucleobase

Brian T. Sutch, R. Eritja, A. Yang, 2008, Nucleosides, nucleotides & nucleic acids.

Mitoxantrone—A Hypomethylating Agent?

J. Issa, A. Yang, 2003, Cancer biology & therapy.

Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials

A. Yang, C. Britten, B. George, 2022, Cytotherapy.

Development and validation of a model to predict platelet response to romiplostim in patients with lower‐risk myelodysplastic syndromes

G. Mufti, A. Yang, H. Kantarjian, 2014, British journal of haematology.

The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib

A. Yang, David Masiello, G. Gorospe, 2009, Journal of hematology & oncology.

Base Excision Repair of U:G Mismatches at a Mutational Hotspot in the p53 Gene Is More Efficient Than Base Excision Repair of T:G Mismatches in Extracts of Human Colon Tumors1

Christoph, Peter A. Jones, A. Yang, 2006 .

Absence of p53 gene mutations in primary nasopharyngeal carcinomas.

A. Yang, P. Jones, M. Gonzalez-Zulueta, 1992, Cancer research.

A mutant HpaII methyltransferase functions as a mutator enzyme.

A. Yang, P. Jones, J. Zingg, 1995, Nucleic acids research.

Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial

S. Groshen, A. Yang, S. Kummar, 2017, Clinical Cancer Research.

The Mutational Burden of 5-Methylcytosine

Peter A. Jones, A. Yang, A. Shibata, 1996 .

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide

R. Larson, A. Yang, E. Wang, 2012, Journal of Hematology & Oncology.

Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial

G. Mufti, A. Yang, H. Kantarjian, 2014, Leukemia.

Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS): Follow-up AML and Survival Results of a Randomized, Double-Blind, Placebo (PBO)-Controlled Study

W. Wiktor-Jedrzejczak, G. Mufti, G. Gaidano, 2012 .

Phase I/II Study of MGCD0103, an Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, in Combination with 5-Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML).

A. Yang, H. Kantarjian, G. Garcia-Manero, 2007 .

The failure of epigenetic combination therapy for cancer and what it might be telling us about DNA methylation inhibitors.

A. Yang, Brandon J Yang, 2016, Epigenomics.

A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine

P. Greenberg, A. Yang, G. Garcia-Manero, 2013, Leukemia & lymphoma.

Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndrome (MDS): Results of a Randomized, Double-Blind, Placebo(PBO)-Controlled Study

W. Jędrzejczak, G. Mufti, G. Gaidano, 2011 .

Update from an Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim In Thrombocytopenic Patients (Pts) with Myelodysplastic Syndromes (MDS)

R. Larson, A. Yang, H. Kantarjian, 2009 .

A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome

J. Issa, P. Marks, A. Yang, 2014, British journal of haematology.

Evaluating new treatment options for MDS.

A. Yang, G. Garcia-Manero, M. Jagasia, 2007, Clinical advances in hematology & oncology : H&O.

Development and Validation of a Model to Predict Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndromes (MDS).

G. Mufti, A. Yang, H. Kantarjian, 2012 .

Methylation inhibitors can increase the rate of cytosine deamination by (cytosine-5)-DNA methyltransferase.

A. Yang, P. Jones, J. Zingg, 1996, Nucleic acids research.

Human p16γ, a novel transcriptional variant of p16INK4A, coexpresses with p16INK4A in cancer cells and inhibits cell-cycle progression

Trees-Juen Chuang, A. Yang, M. Tsai, 2007, Oncogene.

Human p16gamma, a novel transcriptional variant of p16(INK4A), coexpresses with p16(INK4A) in cancer cells and inhibits cell-cycle progression.

Trees-Juen Chuang, A. Yang, M. Tsai, 2007, Oncogene.

Comment on "Chromosomal Instability and Tumors Promoted by DNA Hypomethylation" and "Induction of Tumors in Mice by Genomic Hypomethylation"

J. Issa, A. Yang, M. Estécio, 2003, Science.

Effect of Cytarabine and Decitabine in Combination in Human Leukemic Cell Lines

J. Issa, J. Jelinek, A. Yang, 2007, Clinical Cancer Research.

Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2′-deoxycytidine

Peter A. Jones, A. Yang, G. Liang, 2005, Molecular Cancer Therapeutics.

Widespread Epigenetic Abnormalities Suggest a Broad DNA Methylation Erasure Defect in Abnormal Human Sperm

P. Laird, K. Siegmund, V. Cortessis, 2007, PloS one.

Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1–risk myelodysplastic syndrome and thrombocytopenia

W. Wiktor-Jedrzejczak, G. Mufti, G. Gaidano, 2014, Cancer.

Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition

H. Byun, A. Yang, S. Choi, 2007, British journal of haematology.

Carcinogenesis Mechanisms for the Involvement of DNA Methylation in Colon Updated

Peter A. Jones, Tudung T Nguyen, R. Beart, 2006 .

Mechanisms for the involvement of DNA methylation in colon carcinogenesis.

R. Beart, A. Yang, P. Jones, 1996, Cancer research.

Rapid and quantitative method of allele-specific DNA methylation analysis.

P. Laird, S. Ingles, M. Campan, 2006, BioTechniques.

Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.

R. Beart, A. Yang, P. Jones, 1995, Cancer research.

Predictors of global methylation levels in blood DNA of healthy subjects: a combined analysis.

P. Vokonas, J. Schwartz, L. Hou, 2012, International journal of epidemiology.

Long-term Epigenetic Therapy with Oral Zebularine Has Minimal Side Effects and Prevents Intestinal Tumors in Mice

Peter A. Jones, P. Laird, T. Long, 2008, Cancer Prevention Research.

Hypomethylation of a LINE-1 Promoter Activates an Alternate Transcript of the MET Oncogene in Bladders with Cancer

Peter A. Jones, K. Siegmund, H. Byun, 2010, PLoS genetics.

Identification of preferential target sites for human DNA methyltransferases

Wange Lu, Si Ho Choi, Kyu Heo, 2010, Nucleic Acids Res..

Impact of Chromosomal Rearrangement upon DNA Methylation Patterns in Leukemia

K. Siegmund, H. Byun, A. Yang, 2017, Open medicine.

LINE-1 Hypomethylation in Cancer Is Highly Variable and Inversely Correlated with Microsatellite Instability

J. Issa, J. Jelinek, Lanlan Shen, 2007, PloS one.

Selective Anchoring of DNA Methyltransferases 3A and 3B to Nucleosomes Containing Methylated DNA

Peter A. Jones, Shinwu Jeong, A. Yang, 2009, Molecular and Cellular Biology.

Mono-allelic retrotransposon insertion addresses epigenetic transcriptional repression in human genome

H. Byun, A. Yang, K. Heo, 2012, Journal of Biomedical Science.

Two molecular pathways to transitional cell carcinoma of the bladder.

R. Cote, A. Yang, S. Lerner, 1994, Cancer research.

DNA Methylation profiling of chronic myelogenous leukemia in relationship to genomic translocation

K. Siegmund, H. Byun, A. Yang, 2013 .

Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors.

A. Yang, S. Talwar, L. Cowan, 2010, Epigenomics.

Changes in DNA methylation of tandem DNA repeats are different from interspersed repeats in cancer

H. Byun, A. Yang, G. Garcia-Manero, 2009, International journal of cancer.

Gender and ethnic differences in chronic myelogenous leukemia prognosis and treatment response: a single-institution retrospective study

A. Yang, Dongyun Yang, David Masiello, 2009, Journal of hematology & oncology.

LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors

Peter A. Jones, S. Groshen, D. Weisenberger, 2009, Epigenetics.

FACT-mediated exchange of histone variant H2AX regulated by phosphorylation of H2AX and ADP-ribosylation of Spt16.

M. Lieber, A. Yang, S. Choi, 2008, Molecular cell.

Phase I/II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML)

A. Yang, G. Garcia-Manero, C. Maroun, 2007 .

Base excision repair of U:G mismatches at a mutational hotspot in the p53 gene is more efficient than base excision repair of T:G mismatches in extracts of human colon tumors.

R. Beart, A. Yang, P. Jones, 1995, Cancer research.

Lack of increases in methylation at three CpG-rich genomic loci in non-mitotic adult tissues during aging

S. Tavaré, G. Kanel, D. Shibata, 2007, BMC Medical Genetics.

2'-Deoxy-N4-[2-(4-nitrophenyl)ethoxycarbonyl]-5-azacytidine: a novel inhibitor of DNA methyltransferase that requires activation by human carboxylesterase 1.

P. Laird, B. Trinh, H. Byun, 2008, Cancer letters.

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.

Chris A. Nasrallah, J. Herman, J. Licht, 2009, Blood.

A phase I biological study of azacitidine (VidazaTM) to determine the optimal dose to inhibit DNA methylation

S. Groshen, H. Byun, A. Yang, 2010, Epigenetics.

HhaI and HpaII DNA methyltransferases bind DNA mismatches, methylate uracil and block DNA repair.

A. Yang, P. Jones, J. Zingg, 1995, Nucleic acids research.

Increased BCR promoter DNA methylation status strongly correlates with favorable response to imatinib in chronic myeloid leukemia patients.

H. Byun, A. Yang, B. Kim, 2011, Oncology letters.

Advances in Brief Base Excision Repair of U : G Mismatches at a Mutational Hotspot in the p 53 Gene Is More Efficient Than Base Excision Repair of T : G Mismatches in Extracts of Human Colon Tumors 1

Peter A. Jones, R. Beart, A. Yang, 2006 .

The rate of CpG mutation in Alu repetitive elements within the p53 tumor suppressor gene in the primate germline.

J. Buckley, A. Yang, P. Jones, 1996, Journal of molecular biology.

Epigenetic therapies have demonstrated clear benefit in patients with some cancers via randomized clinical trials.

A. Yang, Brandon J Yang, 2016 .

Nilotinib-Associated Molecular Responses Achieved in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients with a Suboptimal Molecular Response to Imatinib.

J. Radich, A. Yang, D. DeAngelo, 2009 .

Multiple Doses of Intravenous Pegylated Asparaginase with a “Pediatric-like” Protocol in Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL): Toxicity, Clinical Outcome and Low Rate of Anti Asparaginase Antibody Formation.

A. Yang, D. Douer, K. Watkins, 2009 .

AMD3100 sensitizes acute lymphoblastic leukemia cells to chemotherapy in vivo

N. Heisterkamp, J. Groffen, A. Yang, 2011, Blood cancer journal.

MP13-07 IMPROVED EFFICACY OF ADJUVANT, SINGLE DOSE INTRAVESICAL APAZIQUONE BY TIMING POST-RESECTION IN TWO DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 STUDIES IN NON-MUSCLE INVASIVE BLADDER CANCER

A. Yang, L. F. Allen, M. Soloway, 2016 .

Phase I trial of fenretinide (4-HPR) intravenous emulsion for hematologic malignancies

S. Groshen, A. Yang, S. Kummar, 2007 .

Phase I/II Study of the Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor MGCD0103 in Combination with Azacitidine in Patients (pts) with High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML).

J. Issa, A. Yang, H. Kantarjian, 2006 .

FACT-mediated exchange of histone variant H2AX regulated by phosphorylation of H2AX and ADP-ribosylation of Spt16.

M. Lieber, A. Yang, S. Choi, 2008, Molecular cell.